PASADENA, Calif. -- (BUSINESS WIRE) -- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at two upcoming investor conferences.
Scheduled presentations include the following:
Wells Fargo 2014 Healthcare Conference – Boston
June 17, 2014 – At 1:45 p.m. EDT Christopher Anzalone, Ph.D., President and Chief Executive Officer, will deliver a corporate presentation, and at 2:20 p.m. EDT he will participate in the “Gene Manipulation” panel discussion
Piper Jaffray GenomeRx Symposium – New York
June 23, 2014 – At 3:30 p.m. EDT David Lewis, Ph.D., Chief Scientific Officer, will participate in the “RNA/DNA: Getting It Where You Need It” panel discussion
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to firstname.lastname@example.org.